Calquence is a kinase inhibitor used for the treatment of adult patients with:
Mantle cell lymphoma (MCL) who have previously received at least one therapy.
Small lymphocytic lymphoma (SLL) or Chronic lymphocytic leukemia (CLL).
Recommended Dosage: For those with MCL, CLL, or SLL, the recommended dose of Calquence as Monotherapy is 100 mg taken by mouth approximately every 12 hours until the disease is progressive or unacceptable toxicity occurs.
For those with previously untreated CLL or SLL, the recommended dose of Calquence in Combination with Obinutuzumab is 100 mg taken by mouth approximately every 12 hours until the disease is progressive or unacceptable toxicity occurs. Initiate treatment at Cycle 1 (1 cycle = 28 days). Initiate obinutuzumab at Cycle 2 for a total of six cycles. The medication Calquence should be administered prior to obinutuzumab when given on the same day.
Do not open, break or chew the capsules but swallow as whole with water. Do not chew, crush, dissolve, or cut the Calquence tablets. Take dosage with or without food. In case a dose is missed by more than three hours, it should be skipped and the very next dose should be taken at its regularly scheduled time. It is not advisable to take extra capsules to make up for a missed dose.